Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2007-01-02
2007-01-02
Balasubramanian, Venkataraman (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C514S246000
Reexamination Certificate
active
10358652
ABSTRACT:
Corticotropin releasing factor (CRF) antagonists of Formula (I):and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
REFERENCES:
patent: 6191131 (2001-02-01), He et al.
patent: 6194410 (2001-02-01), Bos et al.
patent: 6218397 (2001-04-01), Chen
patent: 6642230 (2003-11-01), Wilde et al.
patent: 2124016 (1998-12-01), None
patent: 97100192 (1999-02-01), None
patent: 99105137 (2001-01-01), None
patent: 2201929 (2003-04-01), None
patent: 2221799 (2004-01-01), None
patent: WO 95/10506 (1995-04-01), None
patent: WO 95/33750 (1995-12-01), None
patent: WO 97/35539 (1997-10-01), None
patent: WO 97/35846 (1997-10-01), None
patent: WO 97/44308 (1997-11-01), None
patent: WO 98/03510 (1998-01-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 99/11643 (1999-03-01), None
patent: WO 99/38868 (1999-08-01), None
patent: WO 99/51608 (1999-10-01), None
patent: WO 00/01675 (2000-01-01), None
Arató, M., et al., “Elevated CSF CRF in suicide victims,”Biol Psychiatry, 1989, 25, 355-359.
Banki, C.M., et al., “CSF corticotrophin-releasing factor-like immunoreactivity in depression and schizophrenia,”Am. J. Psychiatry, Jul. 1987, 873-877.
Berridge, C.W., et al., “A corticotrophin-releasing factor antagonist reverses the stress-induced changes of exploratory behavior in mice,”Hormones and Behavior, 1987, 21, 393-401.
Berridge, C.W., et al., “Corticotropin-releasing factor elicits naloxone sensitive stress-like alterations in exploratory behavior in mice,”Regulatory Peptides, 1986, 16, 83-93.
Blalock, J.E., “A molecular basis for bidirectional communication between the immune and neuroendocrine systems,”PhysiologicalReviews, Jan. 1989, 69(1), 1-32.
Britton, K.T., et al., “Chlordiazepoxide attenuates response suppression induced by corticotrophin-releasing factor in the conflict test,”Psychopharmacology, 1985, 86, 170-174.
Britton, K.T., et al., “Corticotropin releasing factor and amphetamine exaggerate partial agonist properties of benzodiazepine antagonist Ro 15-1788,”Psychopharmacology, 1988, 94, 306-311.
Britton, D.R., et al., “Intraventricular corticotrophin-releasing factor enhances behavioral effects of novelty,”Life Sciences, May 12, 1982, 31(4), 363-367.
Bundgard, H.,Advanced Drug Delivery Reviews, 1992, 8, 1-38.
Chrousos, G.P., et al.,Int. J. Obesity, 2000, 24 (Supp. 2), S50-S55.
De Souza, E.B., et al., “Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: An autoradiographic study,”J. Neuroscience, Dec. 1985, 5(12), 3189-3203.
De Souza, E.B., “CRH defects in alzheimer's and other neurologic diseases,”Hospital Practice, Sep. 15, 1988, 59-71.
Dunn, A.J., et al., “Physiological and behavioral responses to corticotrophin-releasing factor administration: is CRF a mediator of anxiety or stress reponses?,”Brain Research Reviews, 1990, 15, 71-100.
France, R.D., et al., “CSF corticotrophin-releasing factor-like immunoactivity in chronic pain patients with and without major depression,”Biol. Psychiatry, 1988, 23, 86-88.
Gilligan, P.J., et al.,J. Med. Chem., 2000, 43, 1641-1660.
Gold, P.W., et al., “Psychiatric implications of basic and clinical studies with corticotrophin-releasing factor,”Am. J. Psychiatry, May 1984, 141(5), 619-627.
Gold, P.W., et al.,New Eng. J. Med., 1986, 314, 1129.
Grigoriadis, D.E., et al., “Effects of chronic antidepressant and benzodiazepine treatment on corticotrophin-releasing-factor receptors in rat brain and pituitary,”Neuropsychopharmacology, 1989, 2(1), 53-60.
Holsboer, F., et al., “Acth and multisteroid responses to corticotrophin-releasing factor in depressive illness: Relationship to multisteroid responses after acth stimulation and dexamethasone suppression,”Psychoneuroendocrinology, 1984, 9(2), 147-160.
Koob, G.F., “Stress, corticotrophin-releasing factor, and behavior,”Perspectives on Behavioral Medicine, 1985, 2, 39-52.
Koob, G.F.,Ann. N.Y. Acad. Sci., 2000, 909, 170-185.
Krogsgaard-Larsen, et al., “Design and applications of prodrugs,”A Textbook of Drug Design and Development, 1991,Chapter 5, 113-191.
McCarthy, et al.,Cuur. Pharm. Res., 1999, 5, 289-315.
Maillot, C., et al.,Gastroenterology, 2000, 119, 1569-1579.
Morley, J.E., et al., “Minireview—neuropeptides: conductors of the immune orchestra,”Life Sciences, 1987, 41, 527-544.
Mastorakos, G., et al.,Ann. N.Y. Acad. Sci., 2000, 900, 95-106.
Nakeya, N., et al.,Chem. Pharm. Bull., 1984, 32, 692.
Nemeroff, C.B., et al., “Reduced corticotrophin releasing factor binding sites in the frontal cortex of suicide victims,”Arch Gen. Psychiatry, Jun. 1988, 45, 577-579.
Nemeroff, C.B., “Elevated concentrations of CSF corticotrophin-releasing factor-like immunoreactivity in depressed patients,”Science, Dec. 14, 1984, 226, 1342-1344.
Nemeroff, C.B., “Corticotropin-releasing factor: basic and clinical studies of a neuropeptide,”CRC Press, Inc., 1990, 221-224.
Newport, D.J., et al.,Curr. Opin. Neurobiology, 2000, 10, 211-218.
Owens, M.J., et al.,Expert Opin. Invest. Drugs, 1999, 8, 1849-1858.
Remington's Pharmaceutical Sciences, 17thEd., p. 1419.
Rivier, J., et al., “Characterization of rat hypothalamic corticotrophin-releasing factor,”Proc. Nat. Acad. Sci. USA, Aug. 1983, 80, 4851-4855.
Sapolsky, R.M., “Hypercortisolism among socially subordinate wild baboons originates at the CNS level,”Arch. Gen. Psychiatry, Nov. 1989, 46, 1047-1051.
Swerdlow, N.R., et al., “Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide,”Psychopharmacology, 1986, 88, 147-152.
Webster, E., et al.,Ann. N.Y. Acad. Sci., 1998, 840, 21-32.
Widder, K., et al.,Ed. Academic Press, 1985, 42, 309-396.
Vale, W., et al., “Characterization of a 41-risidue ovine hypothalamic peptide that stimulates secretion of corticotrophin and β-endorphin,”Science, Sep. 1981, 213, 1394-1397.
Vale, W., et al., “Chemical and biological characterization of corticotrophin releasing factor,”Recent Progress in Hormone Research, 1983, 39, 245-270.
J. Pharmaceutical Sciences, 1988, 77, 285.
Mitchell, A.J., “The role of corticotrophin releasing factor in depressive illness: a critical review,”Neurosci Biobehav Rev, Sep. 1998, 5, 635-651, Abstract, 1 page.
He, Liqi, et al. 4-(1,3-dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl) pyrazolo [1,5-a]-1,3,5-triazine: A Potent, Orally Bioavailable CRF1Receptor Antagonist, Journal of Medicinal Chemistry, American Chemical Society, Washington, US., vol. 43, 2000, pp. 449-456, XP002196777, ISSN: 0022-2623.
Wermuth et al.; Molecular Variations Based on Isosteric Replacement; The Practice of Medicinal Chemistry, 1996, pp. 203-237, XP 002190259.
Balasubramanian Venkataraman
Bristol-Myers Squibb Pharma Company
Hoffman & Baron LLP
Makujina Shah R.
LandOfFree
4-(2-butylamino)-2,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-(2-butylamino)-2,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(2-butylamino)-2,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3781978